About
The OMERACT ANCA-Associated Vasculitis (AAV) Working Group aims to improve how domains are measured in ANCA-associated vasculitis clinical trials. Building on the endorsed OMERACT core domain set, the group works to define and measure treatment response more precisely, ensuring that domain assessment reflects both clinical manifestations and patient experience.
Through international collaboration and Delphi consensus studies involving patients and clinicians, the group has identified key domains for response assessment, including disease activity, patient-reported outcomes, organ damage, and mortality. Current efforts focus on developing and validating composite response criteria that capture the multidimensional nature of AAV and support more consistent, patient-centered evaluation of therapies.
Current Stage in the OMERACT Process
The team is finalizing validation work for its composite response criteria, developed in collaboration with ACR and EULAR.
Latest Update
The group is finalizing a composite measure to define treatment response criteria. The project is nearly complete, with final validation underway and manuscript preparation in progress.
OMERACT Endorsed Core Domain Set for Clinical Trials in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Recent Working Group Publications
- Quinn, Kaitlin A., et al. “Developing a Composite Outcome Tool to Measure Response to Treatment in ANCA-Associated Vasculitis: A Mixed Methods Study from OMERACT 2020.” Seminars in Arthritis and Rheumatism, vol. 51, no. 5, 2021, pp. 1134–38, https://doi.org/10.1016/j.semarthrit.2021.07.001.